Al's Comment:

 This is remarkable results for a vaccine therapy.  This is the first reported results of a treatment used for brain tumors under the Right To Try law.   They treated patients with recurrent Glioblastoma who historically lived an average of 8 months.  With this treatment, average survival was 19.6 months, with 25% of patients alive at the end of the trial at about the 40 month mark.   They are tweaking the protocol to make it work even better. There was minimal side effects.     


Posted on: 09/22/2022

A Prospective, Cohort Study of SITOIGANAP to Treat Glioblastoma When Given in Combination With Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Nivolumab or Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Pembrolizumab in Patients Who Failed Prior Treatment With Surgical Resection, Radiation, and Temozolomide

 


Click HERE to return to brain tumor news headlines.


Our privacy / cookie policy has changed.
Click
HERE to read it!